Role of glucagon-like peptide-1 analogue versus amylin as an adjuvant therapy in type 1 diabetes in a closed loop setting with ePID algorithm.

Renukuntla VS, Ramchandani N, Trast J, Cantwell M, Heptulla RA

Journal of diabetes science and technology16 Jul 2014Cited by 40 (Europe PMC)

PMID25030181PMCIDPMC4455387DOI10.1177/1932296814542153PepBankPUB-25030181

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

2 results from studies that gave the peptide. 2 results from people.

01HumanRandomized controlled trialEfficacy outcome
In type 1 diabetes during closed-loop insulin delivery, the exenatide versus pramlintide hyperglycemia comparison reported P > .05.
In plain wordsIn type 1 diabetes, the reported comparison of post-meal hyperglycemia between exenatide and pramlintide was not statistically significant.
Peptide
Pramlintide (Symlin)
Outcome
No significant changePostprandial hyperglycemia
Study
n = 10
Comparator
Exenatide with insulin
Outcome group
Glycemic control · Metabolic and weight
Studied dose
30 µgAs given in this study (human).
Source sentences
Summary
Exenatide was found to be significantly better in attenuating postprandial hyperglycemia as compared to insulin monotherapy (P < .03) and pramlintide (P > .05).
1 context sentence(design, population, supporting numbers)
Summary · context
Subjects with type 1 diabetes (T1DM) on insulin pump therapy were recruited to participate in a 27-hour hospitalized admission on 3 occasions (2-4 weeks apart) and placed on the insulin delivery via CL system in random order to receive (1) insulin alone (control), (2) exenatide 2.5 µg + insulin, (3)…
Report a problemFND-2503018101
02HumanRandomized controlled trialEfficacy outcome
In type 1 diabetes during closed-loop insulin delivery, pramlintide suppressed glucagon less than exenatide.
In plain wordsIn type 1 diabetes, pramlintide suppressed glucagon less than exenatide during closed-loop insulin delivery.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseGlucagon suppression
Study
n = 10
Comparator
Exenatide with insulin
Outcome group
Glycemic control · Metabolic and weight
Studied dose
30 µgAs given in this study (human).
Source sentences
Summary
Glucagon suppression was statistically significant with exenatide (P < .03) as compared to pramlintide.
1 context sentence(design, population, supporting numbers)
Summary · context
Subjects with type 1 diabetes (T1DM) on insulin pump therapy were recruited to participate in a 27-hour hospitalized admission on 3 occasions (2-4 weeks apart) and placed on the insulin delivery via CL system in random order to receive (1) insulin alone (control), (2) exenatide 2.5 µg + insulin, (3)…
Report a problemFND-2503018102

Studies that did not test the peptide alone1

In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Pramlintide (Symlin).

03HumanNot a test of Pramlintide (Symlin) aloneRandomized controlled trialEfficacy outcome
In type 1 diabetes, adjunctive therapies including pramlintide had nonsignificantly lower insulin requirements than insulin monotherapy.
In plain wordsIn type 1 diabetes, adjunctive therapies including pramlintide did not significantly reduce insulin requirements versus insulin alone.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeInsulin requirements
Study
n = 10
Comparator
Insulin monotherapy
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Insulin requirements were lower with adjunctive therapy, but statistically insignificant.
1 context sentence(design, population, supporting numbers)
Summary · context
Subjects with type 1 diabetes (T1DM) on insulin pump therapy were recruited to participate in a 27-hour hospitalized admission on 3 occasions (2-4 weeks apart) and placed on the insulin delivery via CL system in random order to receive (1) insulin alone (control), (2) exenatide 2.5 µg + insulin, (3)…
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).
Report a problemFND-2503018103

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.